Southeast Asia offers a wide range of treatments for the management of hypogonadotropic hypogonadism, a medical condition wherein a person suffers from hypogonadism due to insufficient gonadotropin secretion from the pituitary gland. The condition is treated by diagnosing and addressing its root cause (such as a tumour), managing the symptoms, and with hormone replacement therapy, all of which are available in Southeast Asia. The region is complete with all the advanced medical technology necessary to handle all types of medical conditions, including rare or more complex ones such as hypogonadotropic hypogonadism.
Southeast Asia has been steadily building its reputation in the global medical tourism market over the past several years. The region’s top players, namely Singapore, Thailand, and Malaysia, have collectively invested in the region’s medical infrastructure by continuously improving their healthcare systems and supporting their hospitals and medical professionals.
Malaysia is particularly a good choice for the treatment of endocrine problems. In 2015, the country was chosen as the site for the ASEAN Federation of Endocrine Societies Congress, a scientific meeting that focused on advancing the frontiers of endocrinology in the region.
Despite the high-quality medical care and advanced innovative treatments offered in Southeast Asia, the region continues to be a cheaper alternative to the US and UK in more ways than one. Aside from cheaper medical care, the region also offers low-cost accommodation, cheaper hospital stays, and a lower overall cost of living. This is a major advantage for patients who require long-term therapy for their medical problems. Thus, medical tourists travelling, especially to Thailand and Malaysia, can save up to 70% of their overall costs compared to when they travel to the US and the UK.